Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
Foghorn Therapeutics (NASDAQ: FHTX) has reported its Q1 2025 financial results and corporate updates. The company's lead candidate, FHD-909, is advancing in Phase 1 dose escalation trials for SMARCA4-mutated cancers, primarily targeting non-small cell lung cancer. Recent data presented at AACR demonstrated synergistic activity with pembrolizumab and KRAS inhibitors. The company is progressing with multiple pipeline programs, including a Selective CBP degrader (targeting IND in 2026), EP300 degrader, and ARID1B degrader programs, with updates expected in H2 2025.
Financially, Foghorn reported Q1 2025 collaboration revenue of $6.0 million, up from $5.1 million in Q1 2024. Net loss improved to $18.8 million compared to $25.0 million in the prior year. The company maintains a strong balance sheet with $220.6 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing runway into 2027.
Foghorn Therapeutics (NASDAQ: FHTX) ha comunicato i risultati finanziari del primo trimestre 2025 e aggiornamenti aziendali. Il candidato principale dell'azienda, FHD-909, sta avanzando nelle sperimentazioni di fase 1 per l'escalation della dose in tumori con mutazione SMARCA4, concentrandosi principalmente sul carcinoma polmonare non a piccole cellule. I dati recenti presentati all'AACR hanno evidenziato un'attività sinergica con pembrolizumab e inibitori di KRAS. L'azienda sta portando avanti diversi programmi in pipeline, tra cui un degrader selettivo di CBP (con IND previsto per il 2026), un degrader di EP300 e un degrader di ARID1B, con aggiornamenti attesi nella seconda metà del 2025.
Dal punto di vista finanziario, Foghorn ha registrato nel primo trimestre 2025 ricavi da collaborazioni per 6,0 milioni di dollari, in aumento rispetto ai 5,1 milioni del primo trimestre 2024. La perdita netta è migliorata a 18,8 milioni di dollari rispetto ai 25,0 milioni dell'anno precedente. L'azienda mantiene un solido bilancio con 220,6 milioni di dollari in liquidità, equivalenti di cassa e titoli negoziabili al 31 marzo 2025, garantendo risorse finanziarie fino al 2027.
Foghorn Therapeutics (NASDAQ: FHTX) ha informado sus resultados financieros del primer trimestre de 2025 y actualizaciones corporativas. El candidato principal de la compañía, FHD-909, avanza en ensayos de escalada de dosis de fase 1 para cánceres con mutación SMARCA4, enfocándose principalmente en el cáncer de pulmón no microcítico. Datos recientes presentados en AACR mostraron actividad sinérgica con pembrolizumab e inhibidores de KRAS. La empresa continúa desarrollando múltiples programas en su pipeline, incluyendo un degradador selectivo de CBP (con IND previsto para 2026), programas de degradadores de EP300 y ARID1B, con actualizaciones esperadas en la segunda mitad de 2025.
En cuanto a finanzas, Foghorn reportó ingresos por colaboraciones de 6,0 millones de dólares en el primer trimestre de 2025, un aumento respecto a los 5,1 millones en el primer trimestre de 2024. La pérdida neta mejoró a 18,8 millones de dólares comparado con 25,0 millones del año anterior. La compañía mantiene un balance sólido con 220,6 millones de dólares en efectivo, equivalentes y valores negociables al 31 de marzo de 2025, proporcionando recursos financieros hasta 2027.
Foghorn Therapeutics (NASDAQ: FHTX)는 2025년 1분기 재무 실적 및 기업 업데이트를 발표했습니다. 회사의 주요 후보물질인 FHD-909는 SMARCA4 변이 암에 대한 1상 용량 증량 시험을 진행 중이며, 주로 비소세포폐암을 대상으로 하고 있습니다. 최근 AACR에서 발표된 데이터는 펨브롤리주맙 및 KRAS 억제제와의 시너지 효과를 보여주었습니다. 회사는 선택적 CBP 분해제(2026년 IND 목표), EP300 분해제, ARID1B 분해제 프로그램 등 다수의 파이프라인 프로그램을 진행 중이며, 2025년 하반기에 업데이트가 예정되어 있습니다.
재무적으로 Foghorn은 2025년 1분기 협력 수익으로 600만 달러를 보고했으며, 이는 2024년 1분기의 510만 달러에서 증가한 수치입니다. 순손실은 전년도의 2500만 달러에서 개선되어 1880만 달러를 기록했습니다. 회사는 2025년 3월 31일 기준 현금, 현금성 자산 및 시장성 증권으로 2억 2060만 달러를 보유하고 있어 2027년까지 운영 자금을 확보하고 있습니다.
Foghorn Therapeutics (NASDAQ : FHTX) a publié ses résultats financiers du premier trimestre 2025 ainsi que des mises à jour corporatives. Le candidat principal de la société, FHD-909, progresse dans les essais de phase 1 d’escalade de dose pour les cancers mutés SMARCA4, ciblant principalement le cancer du poumon non à petites cellules. Des données récentes présentées à l’AACR ont démontré une activité synergique avec le pembrolizumab et les inhibiteurs de KRAS. La société avance sur plusieurs programmes en pipeline, notamment un dégradeur sélectif de CBP (IND prévu en 2026), ainsi que des programmes de dégradeurs EP300 et ARID1B, avec des mises à jour attendues au second semestre 2025.
Sur le plan financier, Foghorn a déclaré un chiffre d'affaires de collaboration de 6,0 millions de dollars au premier trimestre 2025, en hausse par rapport à 5,1 millions au premier trimestre 2024. La perte nette s’est améliorée à 18,8 millions de dollars contre 25,0 millions l’année précédente. La société dispose d’un bilan solide avec 220,6 millions de dollars en liquidités, équivalents de trésorerie et titres négociables au 31 mars 2025, assurant une trésorerie suffisante jusqu’en 2027.
Foghorn Therapeutics (NASDAQ: FHTX) hat seine Finanzergebnisse für das erste Quartal 2025 sowie Unternehmensupdates veröffentlicht. Der Hauptkandidat des Unternehmens, FHD-909, befindet sich in Phase-1-Dosiseskalationsstudien für SMARCA4-mutierte Krebsarten, mit Schwerpunkt auf nicht-kleinzelligem Lungenkrebs. Kürzlich auf der AACR präsentierte Daten zeigten eine synergistische Wirkung mit Pembrolizumab und KRAS-Inhibitoren. Das Unternehmen arbeitet an mehreren Programmen in der Pipeline, darunter ein selektiver CBP-Degrader (IND-Ziel 2026), EP300- und ARID1B-Degrader-Programme, mit Updates erwartet in der zweiten Jahreshälfte 2025.
Finanziell meldete Foghorn im ersten Quartal 2025 Kollaborationsumsätze von 6,0 Millionen US-Dollar, ein Anstieg gegenüber 5,1 Millionen im ersten Quartal 2024. Der Nettoverlust verbesserte sich auf 18,8 Millionen US-Dollar im Vergleich zu 25,0 Millionen im Vorjahr. Das Unternehmen verfügt über eine starke Bilanz mit 220,6 Millionen US-Dollar an liquiden Mitteln, Zahlungsmitteln und marktfähigen Wertpapieren zum 31. März 2025, was eine Finanzierung bis ins Jahr 2027 sichert.
- Strong financial position with $220.6 million cash runway extending into 2027
- Collaboration revenue increased to $6.0 million in Q1 2025 from $5.1 million in Q1 2024
- Net loss improved to $18.8 million from $25.0 million year-over-year
- Research and development expenses decreased to $21.6 million from $25.5 million year-over-year
- Positive preclinical data showing FHD-909's synergistic activity with pembrolizumab and KRAS inhibitors
- None.
Insights
Foghorn shows solid progress on multiple oncology programs with strong cash position, validating their chromatin-targeting platform technology.
Foghorn's Q1 update reveals meaningful progress across their pipeline with particularly encouraging developments for their lead program FHD-909, a selective SMARCA2 inhibitor. The ongoing Phase 1 trial in SMARCA4-mutated cancers (primarily NSCLC) represents a significant opportunity targeting a mutation present in approximately 10% of NSCLC cases. The preclinical combination data with pembrolizumab and KRAS inhibitors presented at AACR is especially promising, suggesting potential expansion opportunities beyond monotherapy.
Their diversified pipeline demonstrates the versatility of their chromatin-targeting platform. The Selective CBP degrader program is advancing toward IND-enabling studies with a 2026 IND filing target. Importantly, new data indicates potential applications beyond EP300-mutant cancers, particularly in ER+ breast cancer when combined with standard treatments. Meanwhile, the Selective EP300 degrader shows anti-proliferative activity across multiple hematologic malignancies, including activity in IMiD-resistant multiple myeloma models—a significant unmet need.
Financially, Foghorn maintains a strong balance sheet with $220.6 million in cash and marketable securities, providing runway into 2027. Their reduced quarterly net loss of $18.8 million compared to $25 million in Q1 2024 reflects improved operational efficiency, with R&D expenses decreasing from $25.5 million to $21.6 million year-over-year. The ongoing Lilly collaboration provides both validation and non-dilutive funding, with quarterly collaboration revenue increasing to $6 million from $5.1 million year-over-year.
The continued advancement of their selective degrader platform technology addressing previously undruggable targets positions Foghorn as a potential leader in chromatin-targeted therapeutics. With multiple program updates expected in H2 2025, there are several near-term catalysts that could drive value creation.
Foghorn's selective chromatin regulators show promising activity in complex cancers with multiple catalysts expected through 2025-2026.
Foghorn's pioneering work in chromatin regulation represents a sophisticated approach to difficult-to-treat cancers. Their lead asset, FHD-909, targets a compelling synthetic lethal relationship in SMARCA4-mutated tumors. By selectively inhibiting SMARCA2 while sparing SMARCA4, the compound induces cancer cell death while potentially preserving normal cell function. This is particularly relevant in NSCLC, where SMARCA4 mutations occur in a defined patient population.
The preclinical combination data presented at AACR demonstrating synergistic activity with pembrolizumab (anti-PD-1) and KRAS inhibitors is particularly noteworthy. This suggests FHD-909 may enhance immune checkpoint inhibitor efficacy and complement targeted therapies addressing KRAS, one of the most common oncogenic drivers in NSCLC. This multimodal potential significantly expands FHD-909's therapeutic possibilities.
Their degrader portfolio addresses the inherent challenges in selectively targeting highly homologous proteins. The selective CBP degrader program elegantly exploits the synthetic lethality between CBP and EP300 when the latter is mutated, while avoiding the toxicity associated with dual inhibition. The expanded activity in ER+ breast cancer when combined with paclitaxel and CDK4/6 inhibitors suggests broader utility beyond EP300-mutant tumors.
Similarly, the EP300 selective degrader's activity in multiple hematologic malignancies, including IMiD-resistant multiple myeloma, addresses significant treatment resistance mechanisms. The achievement of selective ARID1B degradation is technically impressive given the lack of enzymatic activity to target and high homology with ARID1A.
Overall, Foghorn's platform demonstrates remarkable selectivity in addressing challenging protein targets in chromatin regulation, with multiple clinical and preclinical programs progressing toward meaningful development milestones through 2026.
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population
Data presented at AACR show synergistic activity with FHD-909 in combination with pembrolizumab and KRAS inhibitors and support clinical exploration
Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026
Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025
Strong balance sheet with cash, cash equivalents, and marketable securities of
CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended March 31, 2025. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
“In the first quarter, we continued to progress our novel partnered and proprietary programs, and we were pleased to share more details on the pipeline progress at this year’s AACR annual meeting. The FHD-909 Phase 1 dose escalation trial is proceeding apace. Importantly, the FHD-909 combination data with chemotherapies, KRAS inhibitors and pembrolizumab, that was shared at AACR, reinforces the expansive potential of the selective SMARCA2 inhibitor program in non-small cell lung cancer,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. “Initial data defining potential combination opportunities in ER+ breast cancer for our Selective CBP degrader program are encouraging and support potential beyond EP300-mutant cancers. Our Selective EP300 degrader program continues to show anti-proliferative activity in a broad range of hematological malignancies. And lastly, as previously reported, we have achieved selective degradation for our Selective ARID1B program and look forward to providing a program update in 2025.”
Mr. Gottschalk continued, “These advancements with FHD-909 and our pipeline programs underscore our track record and leadership in engineering promising selective therapeutics. With our robust balance sheet and cash runway into 2027, we are in a strong position to deliver significant value with differentiated, high-impact therapeutics in 2025 and beyond.”
Recent Corporate Updates
Data presented at American Association for Cancer Research (AACR) Annual Meeting. In April 2025, Foghorn presented new preclinical data highlighting pipeline progress for potential first-in-class medicines including FHD-909, a SMARCA2 (BRM) selective inhibitor, and the Selective CBP degrader program and Selective EP300 degrader program.
Two Appointments to Board of Directors. In May, Foghorn announced the appointments of Neil Gallagher, M.D., Ph.D. and Stuart Duty, to its Board of Directors.
- Dr. Gallagher brings over 20 years of executive experience at pharmaceutical and biopharmaceutical organizations leading drug development programs across several therapeutic areas, including oncology. Currently he serves as the President, Head of Research and Development at Syndax Pharmaceuticals and held prior clinical development leadership roles at AbbVie, Amgen, Novartis, and AstraZeneca.
- Mr. Duty has over 30 years of executive experience in finance and investment banking in biotechnology and specialty pharmaceuticals. Most recently, he served as a Senior Managing Director at Guggenheim Securities, LLC where he advised senior executives and boards on a range of financing activities and strategic transactions. Previously, he held senior roles at Piper Jaffray and Montgomery Securities and operating roles at Oracle Partners and Curative Technologies.
Second Annual Chromatin Regulation Summit. In May 2025, Foghorn hosted its “Chromatin Regulation Summit: Targeted Protein Degradation and Induced Proximity,” at their corporate headquarters in Cambridge, Massachusetts. The live event featured presentations and panel discussions with world-renowned industry and academic key opinion leaders on current and future applications of targeted protein degradation and induced proximity modalities for the treatment of disease.
Program Overview and Upcoming Milestones
FHD-909 (LY4050784). FHD-909 is a first-in-class oral SMARCA2 selective inhibitor that has demonstrated in preclinical studies to have high selectivity over its closely related paralog SMARCA4, two proteins that are the catalytic engines across all forms of the BAF complex. Selectively blocking SMARCA2 activity is a promising synthetic lethal strategy intended to induce tumor death while sparing healthy cells. SMARCA4 is mutated in up to
- Advancing Phase 1 trial. Ongoing enrollment and dose escalation in the first-in-human Phase 1, multicenter trial for FHD-909 in SMARCA4 mutated cancers, with NSCLC as the primary target population following the dosing of the first patient in October 2024.
- At the AACR Annual Meeting in April 2025, Lilly presented, on behalf of the collaboration, the clinical study design poster for the Phase 1 trial evaluating FHD-909 in patients with SMARCA4 mutated locally advanced or metastatic solid tumors who have exhausted standard treatment options. The primary target population is NSCLC.
- Presented synergistic preclinical data of FHD-909 in combination with pembrolizumab and KRAS inhibitors. Also at the AACR Annual Meeting in April 2025, Lilly, on behalf of the collaboration, made an oral presentation of new preclinical data demonstrating enhanced anti-tumor activity of FHD-909 in combination with standard-of-care chemotherapies, anti-PD-1 pembrolizumab and several novel KRAS inhibitors in NSCLC animal models. The combination data will inform further development plans of FHD-909.
Ongoing strategic collaboration with Lilly. Collaborating with Lilly to create novel oncology medicines that includes a U.S. 50/50 co-development and co-commercialization agreement for Foghorn’s selective SMARCA2 oncology program, including a selective inhibitor and a selective degrader, and an additional undisclosed oncology target. The collaboration also includes three discovery programs from Foghorn’s proprietary Gene Traffic Control® platform.
Selective CBP degrader program. Selectively targets CBP in EP300-mutated cancer cells found in many types of cancer, including bladder, gastric, and endometrial cancers. CBP and EP300 are highly similar acetyltransferases that create a synthetic lethal relationship when EP300 is mutated. Attempts to selectively drug CBP have been challenging due to the high level of similarity between the two proteins, while dual inhibition of CBP/EP300 has been limited by dose-limiting toxicities.
- Presented preclinical combination data with Selective degrader CBP in ER+ breast cancer. In April 2025, preclinical data showing Selective CBP degraders have combinatorial benefit with approved chemotherapies and targeted agents in solid tumors beyond EP300-mutant cancers was presented as a poster at the AACR Annual Meeting
- Synergistic combination activity demonstrated including with paclitaxel and CDK4/6 inhibitor abemaciclib in ER+ breast cancer
- Findings support combination opportunities for selective CBP degraders in solid tumors beyond EP300-mutant cancers
- On track for IND-enabling studies, targeting IND in 2026.
Selective EP300 degrader program. Selective degradation of EP300 for the treatment of hematopoietic malignancies and prostate cancer. Attempts to selectively drug EP300 have been challenging due to the high level of similarity between EP300 and CBP, while dual inhibition of CBP/EP300 has been limited by dose limiting toxicities. EP300 lineage dependencies are established in multiple myeloma and diffuse large B cell lymphoma.
- Presented preclinical data showing combination with diffuse large b-cell lymphoma (DLBCL) and multiple myeloma (MM) Standard-of-Care Treatment (SoC). In April 2025, preclinical data for the Selective EP300 degrader program demonstrating biological activity in hematological malignancies was presented at the AACR Annual Meeting.
- Anti-proliferative activity in a broad range of hematological malignancies in vitro, including DLBCL, MM, and follicular lymphoma
- Combination of EP300 degrader with SoC in both DLBCL and MM are highly synergistic in vitro.
- Selective EP300 degradation is effective in IMiD-resistant MM cell lines.
- Program update expected in H2 2025.
Selective ARID1B degrader program. Selectively targets and degrades ARID1B in ARID1A-mutated cancers. ARID1A is the most mutated subunit in the BAF complex and amongst the most mutated proteins in cancer. These mutations lead to a dependency on ARID1B in several types of cancer, including ovarian, endometrial, colorectal and bladder. Attempts to selectively drug ARID1B have been challenging because of the high degree of similarity between ARID1A and ARID1B and the fact that ARID1B has no enzymatic activity to target.
- ARID1B is a major synthetic lethal target implicated in up to
5% of all solid tumors. - Developed highly potent and selective binders. Preclinical data demonstrated potent and selective small molecule binders to ARID1B.
- Selective degradation of ARID1B achieved. Foghorn has successfully selectively degraded ARID1B and expects to provide an update on the Selective ARID1B degrader program in H2 2025.
Chromatin Biology and Degrader Platform. Foghorn continues to advance its chromatin biology and degrader platform with investments in novel ligases, long-acting injectables, oral delivery, and induced proximity.
First Quarter 2025 Financial Highlights
- Collaboration Revenue. Collaboration revenue was
$6.0 million for the three months ended March 31, 2025, compared to$5.1 million for the three months ended March 31, 2024. The increase was driven by the continued advancement of programs under the Lilly Collaboration Agreement. - Research and Development Expenses. Research and development expenses were
$21.6 million for the three months ended March 31, 2025, compared to$25.5 million for the three months ended March 31, 2024. The decrease is attributed to a decrease in FHD-286 costs of$2.5 million , decreases in personnel-related costs, early development and other research external costs and facilities and IT-related expenses of$2.1 million , partially offset by an increase in Lilly-partnered programs of$0.7 million . - General and Administrative Expenses. General and administrative expenses were
$7.2 million for the three months ended March 31, 2025, compared to$7.7 million for the three months ended March 31, 2024. This decrease was primarily due to lower consulting costs. - Net Loss. Net loss was
$18.8 million for the three months ended March 31, 2025, compared to a net loss of$25.0 million for the three months ended March 31, 2024. - Cash, Cash Equivalents, and Marketable Securities. As of March 31, 2025, the Company had
$220.6 million in cash, cash equivalents, and marketable securities, providing expected cash runway into 2027.
About FHD-909
FHD-909 (LY4050784) is a potent, first-in-class, allosteric, and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in SMARCA4 rely on SMARCA2 for their survival. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4 mutant lung tumor models.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements.” Forward-looking statements include statements regarding the Company’s ongoing Phase 1 trial of FHD-909 in SMARCA4-mutated cancers, pre-clinical product candidates, expected timing of clinical data, expected cash runway, expected timing of regulatory filings, and research efforts and other statements identified by words such as “could,” “may,” “might,” “will,” “likely,” “anticipates,” “intends,” “plans,” “seeks,” “believes,” “estimates,” “expects,” “continues,” “projects” and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding capital market conditions, our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global political, economic, business, competitive, market and regulatory conditions, including risks relating to our clinical trials and other factors set forth under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release speaks only as of the date on which it is made.
| Condensed Consolidated Balance Sheets (In thousands) | |||||||
| March 31, 2025 | December 31, 2024 | ||||||
| Cash, cash equivalents and marketable securities | $ | 220,587 | $ | 243,747 | |||
| All other assets | 38,104 | 40,235 | |||||
| Total assets | $ | 258,691 | $ | 283,982 | |||
| Deferred revenue, total | $ | 274,112 | $ | 280,063 | |||
| All other liabilities | 46,231 | 49,447 | |||||
| Total liabilities | $ | 320,343 | $ | 329,510 | |||
| Total stockholders’ deficit | $ | (61,652 | ) | $ | (45,528 | ) | |
| Total liabilities and stockholders’ deficit | $ | 258,691 | $ | 283,982 | |||
| Condensed Consolidated Statements of Operations (In thousands, except share and per share amounts) | |||||||
| Three Months Ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Collaboration revenue | $ | 5,952 | $ | 5,050 | |||
| Operating expenses: | |||||||
| Research and development | 21,626 | 25,534 | |||||
| General and administrative | 7,239 | 7,710 | |||||
| Total operating expenses | $ | 28,865 | $ | 33,244 | |||
| Loss from operations | $ | (22,913 | ) | $ | (28,194 | ) | |
| Total other income, net | $ | 4,079 | $ | 3,178 | |||
| Net loss | $ | (18,834 | ) | $ | (25,016 | ) | |
| Net loss per share attributable to common stockholders—basic and diluted | (0.30 | ) | (0.59 | ) | |||
| Weighted average common shares outstanding—basic and diluted | 62,848,673 | 42,428,813 | |||||
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
What is the current cash position of Foghorn Therapeutics (FHTX) and how long will it last?
How did Foghorn Therapeutics (FHTX) perform financially in Q1 2025?
What is the status of FHD-909 development at Foghorn Therapeutics?
What are the key pipeline programs at Foghorn Therapeutics (FHTX)?
What are Foghorn Therapeutics' upcoming milestones for 2025-2026?
